Obstructive sleep apnea: standard management and the use of an artificial saliva in a registry study

Belcaro, G; Cornelli, Umberto; Cacchio, M; Feragalli, Beatrice

doi:10.15761/gmo.1000122

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, to the authors best knowledge, this is the first clinical trial using aldiamed ® and a placebo in a randomized way for such a long period (30 days). In addition, the product is registered in the EU as a medical device and has already been successfully studied in a preliminary experiment in sleep apnea [20]. Starting from this consideration, the aim of this randomized double-blind controlled trial was to evaluate the clinical efficacy of an artificial saliva spray in patients with DM compared to a placebo spray through clinical and radiological analyses.…”

Section: Introductionmentioning

confidence: 99%

Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo

Sinjari

Feragalli

Cornelli

et al. 2020

JCM

View full text Add to dashboard Cite

Xerostomia is a symptom frequently present in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM). In the present trial, the activity of an artificial saliva (aldiamed® spray) in comparison to a placebo spray were used to evaluate the xerostomia and the saliva antioxidant capacity (SAT). Sixty patients of both genders with T1DM or T2DM were randomized into two groups of 30 subjects each. The experiment was a double-blind study approved by the Ethics Committee of the “G. d’Annunzio University” of Chieti and Pescara. Moreover, measurements of the stimulated saliva flow rate and the ultrasonography of the submandibular and parotid glands were performed at both the study time points. The results demonstrated statistically significant differences between the treatments in terms of the xerostomia average score. Specifically, the values were at baseline and after 30 days 2.9 ± 1.31 and 3.0 ± 1.44 and 1.4 ± 1.48 and 2.4 ± 0.99 for aldiamed® spray and the placebo, respectively. Meanwhile, no statistically significant differences were shown between the two groups for the other variables, such as the salivary flow rate, the antioxidant capacity of the saliva, and the ultrasonography of the major salivary glands.

show abstract

Section: Introductionmentioning

confidence: 99%

Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo

Sinjari

Feragalli

Cornelli

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

Obstructive sleep apnea: standard management and the use of an artificial saliva in a registry study

Abstract: Background: The wettability of the oral cavity reduces the symptoms of obstructive sleep apnea (OSA).

Cited by 1 publication

References 13 publications

Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo

Artificial Saliva in Diabetic Xerostomia (ASDIX): Double Blind Trial of Aldiamed® Versus Placebo

Contact Info

Product

Resources

About